[Leukinferon in the comprehensive therapy of sepsis in newborns].
Leukinferon was used in adoptive immunotherapy of sepsis in risk group newborns by activation of the donor leukocyte suspension in combination with etiotropic, antitoxic and other agents of chemotherapy. It accelerated the recovery at the average of 7 days in comparison with the control (the routine treatment). The favourable time course of the major immunological indices such as leukocytosis and absolute and relative counts of lymphocytes mainly due to correction of the T-lymphocyte count, NBT and LII impaired by the pathological process was recorded at the average 4 days earlier against the control. By the end of the treatment normalization of the above mentioned indices proved to be more complete. Neither complications of the septic process nor side effects of the immunotherapy were observed.
Nesterov
V V
VV
Beliaev
D L
DL
Kuznestov
V P
VP
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000628:therapy*; D016207:Cytokines / Q000627:therapeutic use*; D004338:Drug Combinations; D006801:Humans; D016219:Immunotherapy, Adoptive; D007231:Infant, Newborn; D007370:Interferon Type I / Q000627:therapeutic use*; D007962:Leukocytes / Q000502:physiology; D012307:Risk Factors
D000276:Adjuvants, Immunologic; D016207:Cytokines; D004338:Drug Combinations; D007370:Interferon Type I; C062252:leukinferon
Ispol'zovanie leĭkinferona v kompleksnom lechenii sepsisa novorozhdennykh.